Testing FGF23 in anemia with and without kidney disease
Part of Blood & lymphatic, Hormones & metabolism clinical trials.
This study looks at a blood hormone called FGF23 and whether it is linked to heart (cardiovascular) problems in people with anemia. It also compares people with anemia who do and do not have chronic kidney disease, which may help researchers understand risk and targets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your hemoglobin level is below 11 g/dL
- Your iron stores are low (ferritin under 100) or your transferrin saturation is under 20%
- You weigh at least 50 kg and have a BMI of 17 or higher
- No recent major bleeding (more than 500 ml) in the last 72 hours
- You have not had blood transfusion in the last 90 days
- You are not currently pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a protein called FGF23, which helps control minerals in your body, changes as kidney disease progresses. By understanding this, doctors may find better ways to manage kidney disease.
This study looks at whether a blood protein called FGF23 is linked to irregular heartbeats in people on long-term hemodialysis (kidney dialysis). It may help doctors better predict heart risks.
This study looks at FGF19 to see if it can improve chronic kidney disease in people who do not have diabetes. Participants may receive FGF19 (and may need extra testing such as muscle biopsies).
This study looks for new markers in blood or urine that may help explain heart (cardiovascular) risk in people with chronic kidney disease. It may help doctors better predict risk, especially in those not yet on dialysis.
This study looks at how often patients with chronic kidney disease also have anemia, and how it is treated in real life in China. Joining could help doctors understand better ways to manage your anemia and kidney condition.
This study looks at how giving phosphate supplements affects a hormone called FGF23 in patients with low blood phosphate levels. It aims to help understand how the body responds to treatment.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.